H
eart failure (HF) is a major cause of morbidity and mortality worldwide, 1 with a particularly poor prognosis in the period immediately after diagnosis. 2 Early risk stratification is important, with implications for initial treatment and intensity of followup. However, there remains a dearth of validated prognosticators in new-onset HF, with the majority of risk prediction tools derived from cohorts of patients with chronic HF. [3] [4] [5] Current risk stratification is heavily reliant on left ventricular (LV) ejection fraction (LVEF), 6 but the limitations of this approach are well documented. 7, 8 In patients with new-onset HF and reduced LVEF (HF-REF), one of the principal aims of initial evaluation is to distinguish between ischemic and nonischemic pathogeneses. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) allows noninvasive detection of myocardial fibrosis 9 and can help to differentiate between ischemic HF and nonischemic dilated cardiomyopathy (DCM). Whereas patients with HF because of ischemic heart disease typically display a subendocardial or transmural pattern of myocardial fibrosis indicating previous myocardial infarction, patients with DCM either have no fibrosis or a characteristic midwall pattern. 9 Our group has already shown that LGE-CMR can refine and redefine diagnosis of HF pathogenesis in newly presenting patients, thereby serving as a clinically robust and cost-effective gatekeeper to coronary angiography. 10 However, its role in the risk stratification of new-onset HF has not been elucidated.
Recent international guidelines suggest that assessment of myocardial fibrosis by LGE-CMR may aid risk stratification in selected patients with HF. 11 Both the presence and extent of myocardial fibrosis on LGE-CMR predict adverse outcomes in patients with HF but specifically in those with chronic HF because of established ischemic [12] [13] [14] [15] and nonischemic pathogeneses. [16] [17] [18] [19] There has not yet been any dedicated study of the prognostic implications of myocardial fibrosis in patients with a new diagnosis of HF-REF, in whom the underlying pathogenesis is initially unclear. Therefore, we evaluated the prognostic significance of myocardial fibrosis in patients presenting with new-onset HF-REF of uncertain pathogenesis.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Patients
The study prospectively enrolled 124 consecutive patients with new-onset HF (symptom onset <6 months before CMR scan), who were referred from 6 designated HF clinics during a 2-year period. This cohort was included in an earlier report, but we now present a new analysis with clinical follow-up. 10 All patients were diagnosed with HF-REF according to standard criteria. 20 Exclusion criteria included any prior known history of ischemic heart disease (previous myocardial infarction or coronary revascularization), angina, or significant valvular disease. Patients with contraindications to LGE-CMR were also excluded. Four patients were excluded after enrollment (2 patients were unable to complete CMR examination because of claustrophobia, 1 patient was found to have aortic regurgitation not identified by echocardiography, 1 patient withdrew consent). The final cohort, therefore, comprised 120 patients with HF of unknown cause and no clinical evidence of ischemic heart disease. After recruitment, patients underwent coronary angiography as part of their routine clinical work-up to identify significant coronary artery disease (>50% luminal stenosis in the left main vessel or >75% stenosis in either the proximal left anterior descending artery or ≥2 epicardial vessels). 21 The study was approved by the local ethics committee, and all participants provided written informed consent.
CMR Protocol
Cine images (Siemens Sonata 1.5T [n=42] and Siemens Avanto [n=78]) were acquired with a steady-state,
CLINICAL PERSPECTIVE
Risk stratification of patients with new-onset heart failure and reduced left ventricular ejection fraction is challenging because many established prognostic markers, including left ventricular ejection fraction, are liable to change substantially in response to guideline-directed heart failure therapies. Identification of more stable and durable markers of long-term risk in the initial months after diagnosis may help guide the use of more intensive treatment strategies, such as device therapy, at an earlier stage in disease trajectory. Myocardial fibrosis, identified by late gadolinium enhancement cardiovascular magnetic resonance, has previously been shown to predict outcomes in established heart failure and reduced left ventricular ejection fraction. In this study, we show that myocardial fibrosis assessment by a single baseline late gadolinium enhancement cardiovascular magnetic resonance in patients with new-onset heart failure and reduced left ventricular ejection fraction provides powerful prognostic information over a protracted period. Even after adjustment for left ventricular ejection fraction, patients with myocardial fibrosis, in either an infarct or midwall pattern, had a 2-to 3-fold increased risk of all-cause mortality. The absence of fibrosis portends a significant warranty period, with an 85% survival rate for a median of 9-year follow-up observed in our cohort. Our findings provide evidence that late gadolinium enhancement cardiovascular magnetic resonance could help to inform decision making in new-onset heart failure and reduced left ventricular ejection fraction patients on advanced HF therapies and treatments for other major comorbidities.
Gulati et al; Fibrosis in New-Onset Heart Failure free-precession, breathhold sequence (echo time/repetition time 1.6/3.2 ms; flip angle, 60°) in standard long-axis planes and sequential contiguous 7-mm short-axis slices (3-mm gap) from the atrioventricular ring to the apex. LGE imaging was performed 10 minutes after intravenous gadoliniumdiethylenetriamine penta-acetic acid (Schering 0.1 mmol/ kg) in identical long-and short-axis planes using an inversion-recovery gradient echo sequence. Inversion times were adjusted to null normal myocardium (typically 280-380 ms; voxel size, 1.7×1.4×8.0 mm), and images were obtained in 2 separate phase-encoding directions to exclude artifact.
CMR Analysis
Images were analyzed with semiautomated software (CMR Tools, Cardiovascular Imaging Solutions, London). A single blinded experienced reader measured right ventricular and LV volumes, LVEF, and LV mass, using standard techniques. 22, 23 Ventricular volumes and LV mass were indexed to body surface area. The presence and pattern of myocardial fibrosis were determined by a separate panel of 3 expert cardiologists blinded to all clinical data. Myocardial fibrosis was judged to be present in areas of LGE, which were visible in both phase-encoding directions and 2 orthogonal views. Patients were categorized as having infarct fibrosis (subendocardial or transmural LGE in the distribution of a coronary artery perfusion territory), midwall fibrosis (LGE confined to the intramural or subepicardial layers without subendocardial involvement in any myocardial segment), or no fibrosis (Figure 1 ). In patients with infarct or midwall fibrosis, an independent reader quantified fibrosis extent as a percentage of LV mass, using the full-width half-maximum technique (CMR42, Circle Cardiovascular Imaging).
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Clinical Follow-Up and End Points
Follow-up data were collected prospectively at 6 monthly intervals for all patients. Clinical events were ascertained through direct patient contact by telephone interview and postal questionnaires, review of clinical correspondence from cardiologists/family practitioners, and examination of medical records after hospitalization. Survival status was established at each follow-up interval from the UK Health and Social Care Information Service. Cause of death was ascertained from collective review of information provided by death certification, medical records for in-hospital deaths, and postmortem results where available. No patient was lost to follow-up.
The predefined primary end point was all-cause mortality. Two secondary composite, time-to-first event, end points were also prespecified: (1) cardiovascular death or aborted sudden cardiac death (SCD); (2) all-cause mortality, HF hospitalization, or aborted SCD. Cardiovascular death was defined as death because of HF, SCD, myocardial infarction, or thromboembolic event. Aborted SCD was defined as an appropriate implantable cardioverter defibrillator (ICD) shock for ventricular arrhythmia, a nonfatal episode of ventricular fibrillation, or sustained ventricular tachycardia (>30 seconds) causing hemodynamic compromise and requiring cardioversion. HF hospitalization was defined as a hospital admission with signs and symptoms of decompensated HF requiring intravenous HF treatment (diuretics, vasodilators, and inotropes).
Statistical Analysis
Continuous data are expressed as mean values±SD or medians with interquartile range as appropriate. The baseline characteristics of study population, stratified by fibrosis pattern, were compared by Kruskal-Wallis test for continuous variables, and χ 2 test for categorical variables. Survival estimates were constructed by the Kaplan-Meier method. The log-rank test was used to compare the Kaplan-Meier survival curves. Univariable Cox proportional hazards models were used to analyze the relationship between baseline covariables and end points, with results presented as hazard ratios (HRs) and 95% CIs. The association between fibrosis pattern/extent and outcome was evaluated in a multivariable Cox model adjusting for established prognostic variables, including age, sex, and LVEF. The proportional hazards assumption was tested and verified for each covariable on the basis of Schoenfeld residuals. The impact of using fibrosis pattern or extent as well as LVEF to predict risk of all-cause mortality, compared with using LVEF alone, was assessed via the change in Harrell C statistic using a nonparametric bootstrap approach to test the significance of the change. Stata version 15 (StatCorp, College Station, TX) was used for all statistical analyses. A 2-tailed P<0.05 was considered statistically significant.
RESULTS
Study Population
One hundred twenty patients with new-onset HF were enrolled, of whom 31 (26%) had infarct fibrosis, 25 ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; HF, heart failure; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; NYHA, New York Heart Association; RV, right ventricular; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; and RVESV, right ventricular end-systolic volume.
*Variable was not normally distributed and is presented as median (upper quartile, lower quartile).
(21%) had midwall fibrosis, and 64 (53%) had no fibrosis. The median extent of infarct fibrosis was 4.4% (interquartile range, 1.5-7.4) and the median extent of midwall fibrosis was 2.4% (interquartile range, 1.3-4.3).
No patient had coexistent infarct and midwall fibrosis. The median duration of HF at the time of enrollment was 59 days (interquartile range, 33-88 days). Table 1 shows the baseline characteristics of the study population stratified by fibrosis pattern. There were no significant differences in age, HF duration, functional status, CMR measures of LV size and function, and prescription of disease-modifying HF medicines between the 3 groups at the time of CMR scanning. Patients with infarct fibrosis were more likely to receive aspirin and statin therapy at enrollment and have significant coronary artery disease.
Follow-Up Data
Event data are summarized in Table 2 . Patients were prospectively followed for a median period of 8.9 years (interquartile range, 8.3-9.5 years). During this period, 35 (29%) patients had a device implanted, including 7 ICDs, 11 cardiac resynchronization therapy pacemaker devices, and 17 cardiac resynchronization therapy defibrillators. Seventeen (14%) patients had coronary revascularization: 8 had percutaneous coronary interventions, 8 had coronary artery bypass surgery, and 1 patient had both. There were 33 deaths during followup, of which 21 (64%) were cardiovascular, including 9 SCDs, 11 because of HF, and 1 death because of acute myocardial infarction. Twenty (17%) patients were hospitalized for HF, and 6 (5%) patients had an aborted SCD.
Primary End Point: All-Cause Mortality
Overall, there were 33 deaths, involving 13 of 31 (41.9%) with infarct fibrosis and 10 of 25 (40.0%) patients with midwall fibrosis. In contrast, only 10 of 64 (15.6%) patients with no fibrosis died during this period (Table 2) . Kaplan-Meier survival curves demonstrated an association between fibrosis pattern and all-cause mortality ( Figure 2A ; Figure IA in Table 4 ). The percentage extent of fibrosis was also independently associated with the primary end point (HR, 1.07; 95% CI, 1.03-1.12; P≤0.001; Table 4 ). The prognostic significance of both fibrosis pattern and extent was retained on multivariable analysis after further adjustment for coronary revascularization or device implantation (Table I in for fibrosis pattern (95% CI of difference, 0.003-0.14; P=0.033) and 0.66 to 0.71 for fibrosis extent (95% CI of difference, 0.00-0.14; P=0.051).
Secondary End Points
The secondary composite end point of cardiovascular death or aborted SCD occurred in 27 (23%) patients (Table 2) , with a higher event rate among patients with infarct or midwall fibrosis ( Figure 2B ; Figure IB in the Data Supplement), and only 4 cardiovascular deaths and 1 aborted SCD in the subgroup with no fibrosis. (Table 4) . The secondary composite end point of all-cause mortality, HF hospitalization or aborted SCD, was reached by 43 (36%) patients (Table 2) . Kaplan-Meier estimates of event-free survival again showed a significant difference in this outcome according to fibrosis pattern ( Figure 2C ; Figure IC in 
DISCUSSION
We found that the detection of myocardial fibrosis by LGE-CMR, either with infarct or midwall pattern, was associated with an increase in all-cause mortality amongst patients with new-onset HF-REF of initially undetermined cause. The prognostic value of fibrosis was independent of LVEF, one of the most important and clinically relevant prognostic markers in current practice. Both the pattern and extent of fibrosis were also predictive of composite outcomes comprising cardiovascular mortality or aborted SCD, and all-cause mortality, aborted SCD, or HF hospitalization. Importantly, the absence of fibrosis at baseline conferred a favorable long-term prognosis with low rates of major adverse cardiovascular events. Furthermore, the combination of fibrosis pattern with LVEF improved risk prediction for all-cause mortality. These findings suggest that detection and quantification of fibrosis constitute valuable markers for early risk stratification in HF-REF irrespective of underlying pathogenesis.
A growing body of observational evidence suggests that noninvasive fibrosis assessment by LGE-CMR constitutes a powerful tool for risk stratification in both ischemic and nonischemic chronic HF. 25, 26 However, the vast majority of studies to date have focused on populations with established and well-characterized disease. [12] [13] [14] [15] [16] [17] [18] [19] Patients with new-onset HF of initially uncertain pathogenesis represent a distinct group that is frequently encountered in clinical practice. Such patients are at particularly high risk in the early phase of their disease course, with a mortality rate 3-to 4-fold higher in the first year after diagnosis compared with subsequent years. [27] [28] [29] During the same high-risk period, decisions on cardiac resynchronization therapy and ICD implantation may be deferred for up to 3 Guideline recommendations on HF treatment depend on measurement of LVEF, which is also used to stratify risk. 30, 31 However, LVEF often improves spontaneously or as a consequence of therapy in the months after diagnosis, which may limit its prognostic utility. In one study of patients with recent-onset HF and severe ventricular dysfunction (LVEF <30%), 43% of participants demonstrated LV recovery to mildly impaired or normal function within 6 months. 32 Similarly, among patients with severe nonischemic cardiomyopathy undergoing ICD implantation within 6 months of diagnosis, 59% no longer met guideline criteria for ICD insertion at 12 months, predominantly because of recovery of LVEF to ≥35%. 33 Prediction of outcome based solely on LVEF is, therefore, challenging in the early stages of HF when patients are also at the highest risk of adverse events. Similar limitation also applies to other prognostic variables, such as New York Heart Association functional class, natriuretic peptides, and renal function, all of which are liable to considerable fluctuation in the first year of treatment. In contrast to these dynamic indices, which may be useful for gauging response to therapy, fibrosis exhibits less variability over time. 34 Moreover, the presence and extent of fibrosis evaluated by LGE-CMR have been shown to determine the likelihood of LV reverse remodeling after therapy in patients with HF because of ischemic and nonischemic pathogeneses. [34] [35] [36] [37] [38] Such observations reinforce the logical premise that dysfunctional myocardium with replacement fibrosis is less amenable to recovery than regions without fibrosis. We limited our investigation to patients with recently diagnosed HF-REF, a substantial proportion of whom might be expected to experience LV reverse remodeling with optimal treatment. Our findings highlight the prognostic value of LGE-CMR in this group and suggest that myocardial fibrosis assessment may serve as a more stable and durable marker of risk in the early stages of HF after diagnosis.
Several of mechanisms may underpin the relationship between fibrosis and adverse outcomes. It is well recognized that myocardial fibrosis provides a substrate for ventricular re-entrant arrhythmia and hence SCD. 39, 40 In addition, because myocardial fibrosis is closely linked to the likelihood of reverse remodeling, it may provide a marker of the severity of the intrinsic pathological processes driving ventricular dysfunction and HF progression. Infarct fibrosis has been shown to correlate with the underlying burden of coronary artery disease and may therefore also signify overall atherosclerotic risk. 12 We found that myocardial fibrosis detection offered independent and incremental prognostic information for all-cause mortality. These findings accord with previous studies of LGE-CMR. Amongst 61 patients with advanced HF because of new-onset nonischemic DCM, midwall fibrosis detected by LGE-CMR was a strong predictor of subsequent death or the need for cardiac transplantation or mechanical circulatory support. 41 The presence of fibrosis was also associated with a range of adverse cardiovascular outcomes in 2 further cohorts of patients with suspected nonischemic cardiomyopathy of recent onset. 42, 43 Although these studies support the potential prognostic value of LGE-CMR in the early evaluation of HF, they were limited by small sample sizes or short duration of follow-up, leading to reliance on broad composite end points. In contrast, the prolonged follow-up and greater number of events in the present study allowed us to demonstrate the prognostic impact of fibrosis on overall survival alone, as well as important nonfatal events. Perhaps, the most remarkable finding from our study was the ability of LGE-CMR to identify a cohort of HF-REF patients with a low long-term risk of adverse cardiovascular outcomes. In patients without CMR evidence of fibrosis, overall survival for a median of 9 years was 85%. Indeed, there were numerically more deaths because of noncardiovascular causes in the subgroup without myocardial fibrosis, reflecting the increased exposure to competing risks that accrues with improved survival. In the diagnostic work-up of HF, ischemic LV dysfunction is conventionally distinguished from DCM by the presence of >50% stenosis in ≥1 epicardial coronary arteries. 44 Previous work by our group has questioned the validity of this simple dichotomous approach and formed the basis for a more refined etiologic classification informed by myocardial fibrosis assessment using LGE-CMR, in addition to luminal angiography. 10 This study now establishes the prognostic implications of these tissue characterization findings. Historically, HF of ischemic pathogenesis has been associated with a poorer prognosis than nonischemic cardiomyopathy. Yet, we observed that the risk of all-cause mortality and adverse cardiovascular outcomes among patients with midwall fibrosis was at least equivalent to patients with prior infarction. These findings concur with a previous investigation, which showed that patients with DCM who exhibited midwall fibrosis had a similar risk of adverse events to those with ischemic cardiomyopathy after cardiac resynchronization therapy implantation while DCM patients without fibrosis had a far superior prognosis. 45 Moreover in the present study, the extent of fibrosis (irrespective of pattern) predicted outcome, suggesting that the burden of myocardial scar is an important prognostic factor regardless of HF pathogenesis.
Such observations are of particular interest in light of recent evidence from the DANISH trial (The Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality) that has questioned the benefit of prophylactic ICD implantation in DCM. 46 The lack of observed benefit from ICD implantation in that trial (which did not use LGE-CMR to select patients) has been attributed, in large measure, to the more favorable prognosis of DCM compared with ischemic cardiomyopathy. 47 Although the present study was not powered to study the impact of fibrosis on SCD per se, it clearly suggests that LGE-CMR may be able to identify a subset of DCM patients with an adverse prognosis and an overall risk profile akin to ischemic cardiomyopathy. The potential contribution of LGE-CMR to stratification of SCD risk in nonischemic cardiomyopathy has recently been recognized in major international guidelines. 11 Given the strong prognostic signal demonstrated in this and other studies, prospective trials are now warranted to examine whether fibrosis imaging can improve clinical outcomes in HF by guiding prophylactic ICD implantation. 48 
Study Limitations
The study population size and event rate limited the number of candidate covariables we could include in our multivariable model. In addition, several well-established prognostic factors in HF, including renal function and natriuretic peptide levels, were not systematically recorded in all patients and not included in our analyses. Further work in larger cohorts is required to assess the incremental value of fibrosis over these and other markers both individually and as part of validated multivariable prognostic scoring systems. We acknowledge that a single tertiary center CMR unit has the potential to attract referral bias. However, we tried to minimize the risk of this by enrolling consecutive patients with newly presenting HF-REF at 5 additional secondary care institutions without in-house CMR. Our study cohort consisted predominantly of patients with mild to moderate HF in sinus rhythm and without clinical features suggestive of ischemic heart disease. Although the population has broad relevance to clinical practice, our findings may not be applicable to patients with more severe or advanced HF. In particular, the rate of SCD or aborted SCD in our cohort was relatively low, reflecting the spectrum of disease severity and high rates of contemporary medical therapy. LGE-CMR detects focal regions of replacement fibrosis. Patients with HF-REF may also exhibit diffuse interstitial fibrosis. Emerging CMR T1-mapping techniques were not in routine clinical use at the inception of the study but may allow quantification of interstitial fibrosis.
Conclusions
In patients with HF of recent onset and uncertain cause, the detection of infarct pattern or midwall myocardial fibrosis by LGE-CMR provides prognostic information independent of that provided by age, sex, and LVEF and improves risk stratification for all-cause mortality. These findings provide an additional rationale for LGE-CMR in this clinical setting beyond its established diagnostic utility. Further study is now required to explore whether changes in management based on knowledge of fibrosis pattern and extent for patients with new-onset HF-REF can improve outcomes.
ARTICLE INFORMATION
